354 related articles for article (PubMed ID: 12571839)
1. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.
Slifman NR; Gershon SK; Lee JH; Edwards ET; Braun MM
Arthritis Rheum; 2003 Feb; 48(2):319-24. PubMed ID: 12571839
[TBL] [Abstract][Full Text] [Related]
2. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
[TBL] [Abstract][Full Text] [Related]
3. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
4. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
[TBL] [Abstract][Full Text] [Related]
5. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
Wolfe F; Michaud K
Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
[TBL] [Abstract][Full Text] [Related]
6. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
[TBL] [Abstract][Full Text] [Related]
7. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.
Brown SL; Greene MH; Gershon SK; Edwards ET; Braun MM
Arthritis Rheum; 2002 Dec; 46(12):3151-8. PubMed ID: 12483718
[TBL] [Abstract][Full Text] [Related]
9. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
10. [Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis].
Pontikaki I; Gerloni V; Gattinara M; Luriati A; Salmaso A; De Marco G; Teruzzi B; Valcamonica E; Fantini F
Reumatismo; 2006; 58(1):31-8. PubMed ID: 16639486
[TBL] [Abstract][Full Text] [Related]
11. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
[TBL] [Abstract][Full Text] [Related]
12. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
[TBL] [Abstract][Full Text] [Related]
13. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events.
Yazici Y; Erkan D; Paget SA
Arthritis Rheum; 2003 Oct; 48(10):2769-72. PubMed ID: 14558081
[TBL] [Abstract][Full Text] [Related]
14. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
Mohan N; Edwards ET; Cupps TR; Slifman N; Lee JH; Siegel JN; Braun MM
J Rheumatol; 2004 Oct; 31(10):1955-8. PubMed ID: 15468359
[TBL] [Abstract][Full Text] [Related]
15. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.
Fautrel B; Sibilia J; Mariette X; Combe B;
Ann Rheum Dis; 2005 Feb; 64(2):262-6. PubMed ID: 15184196
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
Cairns AP; Taggart AJ
Ulster Med J; 2002 Nov; 71(2):101-5. PubMed ID: 12513005
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.
Mohan AK; Coté TR; Block JA; Manadan AM; Siegel JN; Braun MM
Clin Infect Dis; 2004 Aug; 39(3):295-9. PubMed ID: 15306993
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
[TBL] [Abstract][Full Text] [Related]
19. Granulomatous infectious diseases associated with tumor necrosis factor antagonists.
Wallis RS; Broder MS; Wong JY; Hanson ME; Beenhouwer DO
Clin Infect Dis; 2004 May; 38(9):1261-5. PubMed ID: 15127338
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]